AGA Human

Aspartylglucosaminidase Human Recombinant
Cat. No.
BT27336
Source
E.coli.
Synonyms

Aspartylglucosaminidase, AGU, ASRG, GA.

Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

AGA Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 346 amino acids (24-346 a.a.) and having a molecular mass of 37kDa.
AGA is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
Aspartylglucosaminidase, also known as AGA, is an enzyme involved in the breakdown of N-linked oligosaccharides attached to glycoproteins. This enzyme plays a crucial role in the lysosomal degradation of glycoproteins by cleaving the bond between asparagine and N-acetylglucosamine residues. The gene responsible for encoding AGA is classified as a protein-coding gene.
Description
Recombinant human AGA, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 346 amino acids (specifically, residues 24-346). It has a molecular weight of 37 kDa. This protein is engineered with a 23 amino acid His-tag at its N-terminus to facilitate purification, which is carried out using proprietary chromatographic methods.
Physical Appearance
A clear and colorless solution that has been sterilized by filtration.
Formulation
The AGA protein is supplied in a solution at a concentration of 0.5 mg/ml. This solution is buffered with 20mM Tris-HCl at a pH of 8.0 and contains 10% glycerol as a stabilizing agent.
Stability
For short-term storage (up to 4 weeks), the product can be kept at 4°C. For extended storage, it is recommended to freeze the product at -20°C. To ensure optimal stability during long-term storage, consider adding a carrier protein such as HSA or BSA to a final concentration of 0.1%. Repeated freezing and thawing of the product should be avoided.
Purity
The purity of this product is greater than 90% as determined by SDS-PAGE analysis.
Synonyms

Aspartylglucosaminidase, AGU, ASRG, GA.

Source
E.coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSSSPLPLV VNTWPFKNAT EAAWRALASG GSALDAVESG CAMCEREQCD GSVGFGGSPD ELGETTLDAM IMDGTTMDVG AVGDLRRIKN AIGVARKVLE HTTHTLLVGE SATTFAQSMG FINEDLSTTA SQALHSDWLA RNCQPNYWRN VIPDPSKYCG PYKPPGILKQ DIPIHKETED DRGHDTIGMV VIHKTGHIAA GTSTNGIKFK IHGRVGDSPI PGAGAYADDT AGAAAATGNG DILMRFLPSY QAVEYMRRGE DPTIACQKVI SRIQKHFPEF FGAVICANVT GSYGAACNKL STFTQFSFMV YNSEKNQPTE EKVDCI.

Product Science Overview

Introduction

Aspartylglucosaminidase (AGA) is an enzyme that plays a crucial role in the catabolism of N-linked oligosaccharides of glycoproteins. It is an amidohydrolase enzyme that cleaves asparagine from N-acetylglucosamines, which is one of the final steps in the lysosomal breakdown of glycoproteins . The recombinant form of this enzyme, known as human recombinant Aspartylglucosaminidase, is produced using recombinant DNA technology, which allows for the production of large quantities of the enzyme for research and therapeutic purposes.

Aspartylglucosaminuria (AGU)

Aspartylglucosaminidase deficiency leads to a rare lysosomal storage disorder known as Aspartylglucosaminuria (AGU). AGU is a recessively inherited disease that is most prevalent in the Finnish population . This disorder is characterized by the accumulation of glycoasparagines in tissues and body fluids due to the deficient activity of AGA. The clinical manifestations of AGU include progressive intellectual and physical disability, macrocephaly, hernias, and respiratory infections .

Genetic Basis

The genetic basis of AGU involves mutations in the AGA gene. A common mutation in the Finnish population is a single nucleotide change resulting in a cysteine to serine substitution (C163S) in the AGA enzyme protein . This mutation is responsible for 98% of AGU cases in Finland, making carrier detection and prenatal diagnosis relatively straightforward in this population .

Recombinant AGA

Recombinant AGA is produced using recombinant DNA technology, which involves inserting the human AGA gene into a suitable expression system, such as bacteria or mammalian cells, to produce the enzyme in large quantities. This recombinant enzyme can be used for research purposes to study the biochemical properties and functions of AGA, as well as for potential therapeutic applications.

Therapeutic Applications

One of the potential therapeutic applications of recombinant AGA is enzyme replacement therapy (ERT) for AGU patients. In animal models, treatment with recombinant AGA has shown promising results in correcting the pathophysiological characteristics of AGU in non-neuronal tissues . However, enzyme replacement trials in human AGU patients have not yet been reported .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.